The forecast for antiinfective medicine sales in Japan shows a consistent decline from 2024 to 2028, starting at 980.7 million USD in 2024 and falling to 767.2 million USD in 2028.
Comparing year-on-year variation:- 2024 to 2025: -5.5%- 2025 to 2026: -5.8%- 2026 to 2027: -6.1%- 2027 to 2028: -6.4%
The Compound Annual Growth Rate (CAGR) for this period is -5.95%, indicating a steady decrease of nearly 6% per year. In 2023, the value stood at 1035.6 million USD.
Future trends to watch for include potential impacts of telemedicine, changing disease prevalence, and emergent antibiotic resistance on antiinfective medicine sales. Technological advancements and healthcare policy reforms could also significantly influence market dynamics.